Subscribe to RSS
DOI: 10.1055/a-1272-9653
Rheumatische Erkrankungen mit Manifestation am Auge
Ocular manifestations of Rheumatic diseases
Entzündlich-rheumatische Erkrankungen werden häufig mit Schmerzen des Bewegungsapparats und entzündeten Gelenken assoziiert. Tatsächlich handelt es sich jedoch um Multisystemerkrankungen, die alle Organsysteme – und folglich auch die Augen – betreffen können. Der Beitrag geht auf die wichtigsten Augenmanifestationen ein und erklärt, warum und wann eine Augenbeteiligung auch bei vermeintlich fehlenden Symptomen aktiv abgeklärt werden sollte.
Abstract
Pain in the musculoskeletal system and in the joints is what comes to mind first when people talk about rheumatic diseases. However, rheumatic diseases are multisystem disorders that can affect every organ system. Therefore, ocular manifestations are common and can occur in almost every rheumatic disease. On the one hand, they can even precede musculoskeletal manifestations. On the other hand, they can remain unrecognized without a thorough ophthalmologic examination in some disease entities. Consequently, a close cooperation between medical specialties is warranted, to prevent permanent impairment in vision or consequential damage to organs or joints.
The following article thus focuses on the most important ocular manifestations of rheumatic diseases. For example, we address keratoconjunctivitis sicca as a complication in many rheumatic disorders, which include rheumatoid arthritis and, most importantly, Sjogren’s syndrome. Furthermore, we cover uveitis and associated diseases such as spondyloarthritis or sarcoidosis. Also, we discuss giant cell arteritis as a rheumatological emergency. All in all, we aim to give a synopsis of clinical presentations, important diagnostic measures, and current therapeutic options of the above-mentioned disorders.
Publication History
Article published online:
13 July 2021
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Jakob E, Reuland S, Mackensen F. et al. Uveitis subtypes in a german interdisciplinary uveitis center – analysis of 1916 patients. J Rheumatol 2009; 36: 127-136
- 2 Cao Y, Zhang W, Wu J. et al. Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment. J Ophthalmol 2017; 7298026
- 3 Tsirouki T, Dastiridou A, Symeonidis C. et al. A Focus on the Epidemiology of Uveitis. Ocul Immunol Inflamm 2018; 26: 2-16
- 4 Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol 2017; 31: 846-862
- 5 Burrow MK, Patel BC. Keratoconjunctivitis. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020. https://www.ncbi.nlm.nih.gov/books/NBK542279/ ; Stand: 11.05.2021
- 6 Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res 2014; 9: 240-250
- 7 Lemp MA, Baudouin C, Baum J. et al. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007; 5: 75-92
- 8 Craig JP, Nichols KK, Akpek EK. et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15: 276-283
- 9 Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004; 23: 272-285
- 10 Fiehn C, Zierhut M, Becker M. Differenzialdiagnose Uveitis. Dtsch Arztebl 2003; 100: A2514-A2522
- 11 Max R, Lorenz HM, Mackensen F. Augenbeteiligung bei Spondyloarthritiden – HLA B27-assoziierte Uveitis. Z Rheumatol 2010; 69: 397-340
- 12 Gueudry J, Muraine M. Anterior uveitis. J Fr Ophtalmol 2018; 41: e11-e21
- 13 Pleyer U, Pohlmann D, Rademacher J. Anteriore Uveitis: Klinik, diagnostisches Vorgehen und Behandlungsoptionen. Augenheilkunde up2date 2020; 10: 147-161
- 14 Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet 2017; 390: 73-84
- 15 Prasse A. The Diagnosis, Differential Diagnosis, and Treatment of Sarcoidosis. Dtsch Arztebl Int 2016; 113: 565-574
- 16 Schirmer JH, Aries PM, Balzer K. et al S2k Leitlinie Management der Großgefäßvaskulitiden. AWMF Registernummer: 060-007. 2020 https://www.awmf.org/uploads/tx_szleitlinien/060-007k_S2k_Management_Gro%C3%9Fgef%C3%A4%C3%9Fvaskulitiden_2020-08.pdf ; Stand: 29.01.2021
- 17 Buttgereit F, Dejaco C, Matteson EL. et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315: 2442-2458